U S Physical Therapy vs GeneDx
USPH and WGS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How USPH and WGS compare
GeneDx is the larger company, worth 1.7 times as much as U S Physical Therapy ($2.1B against $1.3B).
GeneDx grew revenue faster over the last twelve months (25.4% versus 11.3% for U S Physical Therapy).
U S Physical Therapy keeps more of each dollar of sales as profit, with a net margin of 4.0% compared with −23.4% at GeneDx.
U S Physical Therapy pays a dividend yielding 2.1%; GeneDx does not pay one.
U S Physical Therapy scores higher on the StockData Score (10 against 6 for GeneDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | USPH | WGS |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $2.1B |
| Share price | $85.83 | $71.02 |
| Change, 1 year | −2.6% | −48.3% |
| Change, 5 years | −21.2% | −74.9% |
| Beta (5Y) | 0.76 | 2.07 |
| Employees | 7,294 | 1,300 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 2 | 2 |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/S | 1.6× (better) | 4.7× |
| P/B | 2.9× (better) | 8.7× |
| EV/EBITDA | 15.0× | – |
| P/FCF | 20.0× | – |
| FCF yield | 5.0% (better) | −3.6% |
| Fair value | $80.34 | $31.92 |
| Margin of safety | −6.8% (better) | −122% |
| Growth | ||
| Revenue growth (TTM) | 11.3% | 25.4% (better) |
| Revenue growth, 5Y average | 13.0% | 19.0% (better) |
| Net income growth (TTM) | −15.6% (better) | −7665% |
| EPS growth (TTM) | – | −18300% |
| EPS growth, 5Y average | −10.6% | – |
| Profitability | ||
| Gross margin | 18.7% | 69.4% (better) |
| Operating margin | 9.4% (better) | −20.3% |
| Net margin | 4.0% (better) | −23.4% |
| FCF margin | 7.9% (better) | −16.7% |
| Return on equity | 6.8% (better) | −40.8% |
| Return on invested capital | 8.9% (better) | −36.2% |
| Financial health | ||
| Debt / equity | 0.49 | 0.40 (better) |
| Net debt / EBITDA | 1.99 | – |
| Current ratio | 1.27 | 3.30 (better) |
| Altman Z-score | 2.71 (better) | 1.87 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | – |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 41.3% | – |
| Shareholder yield | 2.1% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 109% | 107% |
| Held by insiders | 2.6% | – |
| Insider net buying, 12 months | −$173K | $85.1M (better) |
| Short interest, % of float | 8.9% | – |
Go deeper
- USPH stock overview
- USPH income statement
- USPH valuation and score
- WGS stock overview
- WGS income statement
- WGS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.